Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results

The 2014 Ebola crisis unfolded like a Hollywood movie, with gruesome deaths, tragic stories, and global panic about its potential spread. Ebola had never spread so far or fast in the known history of the disease. Prior outbreaks were limited to a handful of cases in isolated communities that, while frightening, were easy to contain. But this was different. The outbreak, which stretched from March 2014 to October 2015, with ongoing sporadic cases continuing to occur in Guinea, spread across three countries in Africa, infecting more than 28,000 people and leaving more than 11,300 people dead. It’s a tragic story but it has real consequences in the world of vaccine development. As we... Read More

Topics

Vaccines , Immunoassay Services , Central Laboratories

Despite the fact that tuberculosis (TB) has been curable, it has become a global epidemic that impacts more people every year than HIV/AIDS. The millions of TB patients worldwide suffer from morbidity, mortality and Social Stigma, which can be referred to as a ‘triad of devastation.’ In recognition of World TB Day on March 24, I think it’s important to recognize just how devastating this disease has become due to the increasing spread of drug resistance, and how the clinical trial industry is working together to provide the healthcare industry and patients with a solution.   Bad news and good One of the most shocking statistics about this disease is that roughly one third of the world’s... Read More

Topics

Central Laboratories , Immunoassay Services , Vaccines

Advances in precision medicine have led to a shift in paradigm for oncology research, from targeted therapies that rely largely on tyrosine kinase inhibitors (TKIs) to personalized therapy that can deliver demonstrable improvement in patient response along with considerably lower side effects. At the center of this trend is immunotherapy, in which researchers are developing drugs that harness the patient’s immune system to fight the cancer on its own. This research area has seen the introduction of new drugs, known as immune checkpoint inhibitors that target various pathways such as Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or Programmed cell Death Protein 1 (PD-1). How immunotherapy... Read More

Topics

Biomarkers , Companion Diagnostics